FDA approves Enhertu for two HER2-positive early breast cancer indications

The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early breast cancer. The approval covers the use of Enhertu in both the neoadjuvant and adjuvant treatment settings for adult patients. In the neoadjuvant setting, the therapy is approved for adults with HER2-positive stage 2 or stage 3 breast cancer. Credit: Arif biswas / Shutterstock.com. The US Food and Drug Administration (FDA) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for two new indications in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Data from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials…

Source: Pharmaceutical Technology